Search Results - "Torri, V"

Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out by Proto, C., Ferrara, R., Signorelli, D., Lo Russo, G., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L.M., De Simone, I., Colombo, M.P., Sica, A., Torri, V., Garassino, M.C.

“…•Currently, only patients with PD-L1 TPS ≥ 50% can receive immunotherapy (pembrolizumab) as first line treatment in clinical practice and they account for a…”
Get full text

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research by Pietrantonio, F., Caporale, M., Morano, F., Scartozzi, M., Gloghini, A., De Vita, F., Giommoni, E., Fornaro, L., Aprile, G., Melisi, D., Berenato, R., Mennitto, A., Volpi, C. C., Laterza, M. M., Pusceddu, V., Antonuzzo, L., Vasile, E., Ongaro, E., Simionato, F., de Braud, F., Torri, V., Di Bartolomeo, M.

“…Mechanisms of acquired resistance to trastuzumab‐based treatment in gastric cancer are largely unknown. In this study, we analyzed 22 pairs of tumor samples…”
Get full text

Immunometabolic Status of COVID-19 Cancer Patients by Sica, A, Colombo, M P, Trama, A, Horn, L, Garassino, M C, Torri, V

“…Cancer patients appear to be more likely to be diagnosed with coronavirus disease 2019 (COVID-19). This is supported by the understanding of immunometabolic…”
Get full text

Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation by Zecca, C., Antozzi, C. G., Torri Clerici, V., Ferrazzini, M., Mantegazza, R. E., Rossi, S., Gobbi, C.

“…Background Delayed‐release dimethyl fumarate (DMF) treatment can be associated with reduced lymphocyte and leucocyte counts, which might persist after DMF…”
Get full text

Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’ by Mandala`, M., Clerici, M., Corradino, I., Vitalini, C., Colombini, S., Torri, V., De Pascale, A., Marsoni, S.

“…To investigate the incidence, risk factors and clinical implications of venous thromboembolism (VTE) in advanced cancer patients treated in phase I studies…”
Get full text

A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma by Rosati, G., Ambrosini, G., Barni, S., Andreoni, B., Corradini, G., Luchena, G., Daniele, B., Gaion, F., Oliverio, G., Duro, M., Martignoni, G., Pinna, N., Sozzi, P., Pancera, G., Solina, G., Pavia, G., Pignata, S., Johnson, F., Labianca, R., Apolone, G., Zaniboni, A., Monteforte, M., Negri, E., Torri, V., Mosconi, P., Fossati, R.

“…Colorectal cancer is the third most common and the third most lethal cancer in both men and women in developed countries. About 75% of cases are first…”
Get full text

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial by Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S., Bettini, A., Longo, F., Moscetti, L., Ganzinelli, M., Lauricella, C., Copreni, E., Labianca, R., Martelli, O., Marsoni, S., Broggini, M., Garassino, M.C.

“…The prognostic and predictive role of KRAS mutations in advanced nonsmall-cell lung cancer (NSCLC) is still unclear. TAILOR prospectively assessed the…”
Get full text

The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations by Novello, S, Pinto, C, Torri, V, Porcu, L, Di Maio, M, Tiseo, M, Ceresoli, G, Magnani, C, Silvestri, S, Veltri, A, Papotti, M, Rossi, G, Ricardi, U, Trodella, L, Rea, F, Facciolo, F, Granieri, A, Zagonel, V, Scagliotti, G

“…Abstract Malignant Pleural Mesothelioma (MPM) remains a relevant public health issue, and asbestos exposure is the most relevant risk factor. The incidence has…”
Get full text

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data by Raja, F.A., Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M.K., Vergote, I.B., Gonzalez-Martin, A., Alberts, D.S., Plante, M., Torri, V., Ledermann, J.A.

“…The majority of women with ovarian cancer develop recurrent disease. For patients with a platinum-free interval of >6 months, platinum-based chemotherapy is a…”
Get full text

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data by Arriagada, R, Auperin, A, Burdett, S, Higgins, J P, Johnson, D H, Le Chevalier, T, Le Pechoux, C, Parmar, M K B, Pignon, J P, Souhami, R L, Stephens, R J, Stewart, L A, Tierney, J F, Tribodet, H, van Meerbeeck, J

“…Summary Background Many randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable non-small-cell lung cancer. We undertook…”
Get full text

Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)-a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SICO by Di Giorgio, A, Gerardi, C, Abatini, C, Melotti, G, Bonavina, L, Torri, V, Santullo, F, Garattini, S, De Luca, M, Rulli, Erica, Rulli, Eliana, Pacelli, F

“…At the time of diagnosis, 15-20% of gastric carcinomas are in stage T4 or T4b. Furthermore, 5-20% of patients undergoing potentially curative surgery suffer…”
Get full text

Malignant peritoneal mesothelioma: a multicenter study on 81 cases by Manzini, V. de Pangher, Recchia, L., Cafferata, M., Porta, C., Siena, S., Giannetta, L., Morelli, F., Oniga, F., Bearz, A., Torri, V., Cinquini, M.

“…Malignant peritoneal mesothelioma (MPM) is a rare disease characterized by a difficult diagnosis, different types of presentation, variable course and poor…”
Get full text

Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients by Mandalà, M., Reni, M., Cascinu, S., Barni, S., Floriani, I., Cereda, S., Berardi, R., Mosconi, S., Torri, V., Labianca, R.

“…Background: The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancer patients. Methods: This…”
Get full text

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer by Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., Chiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N.J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C., Scagliotti, G.V.

“…Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In…”
Get full text

The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials by Cascinu, S., Poli, D., Zaniboni, A., Lonardi, S., Labianca, R., Sobrero, A., Rosati, G., Di Bartolomeo, M., Scartozzi, M., Zagonel, V., Pella, N., Banzi, M., Torri, V.

“…Because the role of the primary tumour location in the adjuvant setting has not been clearly established in colon cancer, we analysed the clinical outcome…”
Get full text

Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care by Liberati, A, D'Amico, R, Pifferi, Torri, V, Brazzi, L

“…Pneumonia is an important cause of mortality in intensive care units. The incidence of pneumonia in such patients ranges between 7% and 40%, and the crude…”
Get more information

Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”: [Annals of Oncology 33 (2022) 57-66] by Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., Chiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N.J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C., Scagliotti, G.V.

Get full text

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study by Cazzaniga, M. E., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Di Mauro, P., Cogliati, V., Capici, S., Clivio, L., Torri, V.

“…Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor…”
Get full text

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients by Trevisan, B., Pepe, F. F., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferraù, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Clivio, L., Torri, V., Cazzaniga, M. E.

“…Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and…”
Get full text

Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40 mg: Need for Titration? by Zecca, Chiara, Bellavia, G., Brambilla, L., Gutierrez, L. P., Gerardi, C., Fiori, A. M., Bernardini, L. R., Camera, G., Disanto, G., Petrini, L., Perugini, J., Antozzi, C. G., Torri Clerici, V., Bellino, A., Confalonieri, P. A., Gobbi, C., Mantegazza, R. E., Rossi, S.

“…Background Glatiramer acetate (GA) 20 mg/day (GA20) is associated with immediate post-injection reactions (PIRs). For convenience of use, approved GA 40 mg…”
Get full text